热门资讯> 正文
Janux治疗公司宣布PSMA-TRACTr JANX007 1a阶段剂量升级的中期临床数据和流水线计划的最新情况
2023-07-17 20:02
- Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS
- PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers
- JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities
- PK exposure demonstrated TRACTr activation with lack of TCE accumulation
- No treatment-emergent ADA titers observed
- Janux to host virtual investor event today at 4:00 PM Eastern Time
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
